ppERK2/ERK2 Aptamer Details
ID# 7488
Structure
Chemistry
RNA
Target
ppERK2/ERK2
Category
Protein
Affinity (Kd)
4.7 nM
Length
123
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-rGprGprGprAprGprAprGprCprCprAprUprAprCprCprUprGprAprCprAprAprAprGprAprCprGprCprUprAprGprCprGprAprAprUprUprGprGprUprUprCprCprUprCprAprCprUprCprAprAprAprAprGprUprAprGprGprGprGprAprAprAprGprCprGprUprUprAprUprUprAprAprGprAprAprAprCprCprAprAprAprAprUprUprUprGprAprCprAprGprGprUprUprAprCprGprCprAprUprCprCprUprGprCprAprUprCprCprUprCprCprAprGprGprUprUprAprCprGprCprAprUprCprCp-3'
Molecular Weight: 39558.93
Extinction Coefficient: 1233700
Binding Conditions / Buffer
Selection Buffer (10 mM HEPES (pH 7.5) and 10 mM MgCl2)
Binding Temp: 30°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Seiwert, S., et al. "RNA aptamers as pathway-specific MAP kinase inhibitors." Chemistry and Biology, 7 (2000): 833-843.
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
